Adenovirus COVID-19 Vaccines and Guillain-Barré Syndrome with Facial Paralysis
Ann Neurol
.
2022 Jan;91(1):162-163.
doi: 10.1002/ana.26258.
Epub 2021 Nov 12.
Authors
Antoine Pegat
#
1
,
Alberto Vogrig
#
2
,
Charles Khouri
3
,
Kamel Masmoudi
4
,
Thierry Vial
5
,
Emilien Bernard
1
Affiliations
1
Electroneuromyography and Neuromuscular Disorders Unit, Pierre Wertheimer Neurological Hospital, Hospices Civils de Lyon, Lyon, France.
2
Clinical Neurology, Udine University Hospital, Udine, Italy.
3
Pharmacovigilance Department, Grenoble Alpes University Hospital, Grenoble, France.
4
Regional Pharmacovigilance Center, Clinical Pharmacology Department, Amiens-Picardie University Hospital Center, Amiens, France.
5
Pharmacovigilance Center, Hospital-University Pharmacotoxicology Service, Hospices Civils de Lyon, Lyon, France.
#
Contributed equally.
PMID:
34699065
PMCID:
PMC8652690
DOI:
10.1002/ana.26258
No abstract available
Publication types
Letter
Comment
MeSH terms
Adenoviridae
COVID-19 Vaccines
COVID-19*
Facial Paralysis*
Guillain-Barre Syndrome* / therapy
Humans
SARS-CoV-2
Substances
COVID-19 Vaccines